Astellas invests in CAR-T cell therapy for solid tumours
Drug Discovery World
AUGUST 8, 2023
The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of Poseida and a one-time $25 million payment for first refusal to license allogeneic CAR-T cell therapy P-MUC1C-ALLO1. ” Astellas’ portfolio includes oncolytic viruses, bispecific immune cell engagers, small molecules, and cell therapy platforms.
Let's personalize your content